6WMH | pdb_00006wmh

Next generation monomeric IgG4 Fc

• PDB DOI: https://doi.org/10.2210/pdb6WMH/pdb

• Classification: IMMUNE SYSTEM
• Organism(s): Homo sapiens
• Expression System: Homo sapiens
• Mutation(s): Yes 


• Deposited: 2020-04-21 Released: 2021-09-15 
• Deposition Author(s): Oganesyan, V.Y., Shan, L., van Dyk, N., Dall'Acqua, W.F.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.30 Å
• R-Value Free: 
  0.243 (Depositor), 0.242 (DCC) 
• R-Value Work: 
  0.201 (Depositor), 0.208 (DCC) 
• R-Value Observed: 
  0.203 (Depositor) 

Starting Model: experimental

Literature

In vivo pharmacokinetic enhancement of monomeric Fc and monovalent bispecific designs through structural guidance.

Shan, L., Dyk, N.V., Haskins, N., Cook, K.M., Rosenthal, K.L., Mazor, R., Dragulin-Otto, S., Jiang, Y., Wu, H., Dall'Acqua, W.F., Borrok, M.J., Damschroder, M.M., Oganesyan, V.

(2021) Commun Biol 4: 1048-1048

• PubMed: 34497355 
• DOI: https://doi.org/10.1038/s42003-021-02565-5
• Primary Citation Related Structures: 
  6WIB, 6WMH, 6WNA, 6WOL


• PubMed Abstract: 
  

  In a biologic therapeutic landscape that requires versatility in targeting specificity, valency and half-life modulation, the monomeric Fc fusion platform holds exciting potential for the creation of a class of monovalent protein therapeutics that includes fusion proteins and bispecific targeting molecules. Here we report a structure-guided approach to engineer monomeric Fc molecules to adapt multiple versions of half-life extension modifications. Co-crystal structures of these monomeric Fc variants with Fc neonatal receptor (FcRn) shed light into the binding interactions that could serve as a guide for engineering the half-life of antibody Fc fragments. These engineered monomeric Fc molecules also enabled the generation of a novel monovalent bispecific molecular design, which translated the FcRn binding enhancement to improvement of in vivo serum half-life.

---

Organizational Affiliation: 
• Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA. [e-mail].
Denali Therapeutics, South San Francisco, CA, USA. [e-mail].
Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.
Early Oncology, R&D, AstraZeneca, Gaithersburg, MD, USA.
Division of Cellular and Gene Therapies, FDA Center for Biologics Evaluation and Research, Silver Spring, MD, USA.
Dosage Form Design and Development, R&D, AstraZeneca, Gaithersburg, MD, USA.
Clinical Pharmacology and Safety Science, R&D, AstraZeneca, Gaithersburg, MD, USA.
Janssen BioTherapeutics, Janssen Research and Development, Spring House, PA, USA.
Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA. [e-mail].

Biological Assembly 1  

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 1 assigned by authors.

Biological Assembly Evidence: gel filtration

Biological Assembly 2  

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 2 assigned by authors.

Macromolecule Content 

• Total Structure Weight: 47.58 kDa 
• Atom Count: 3,496 
• Modeled Residue Count: 413 
• Deposited Residue Count: 414 
• Unique protein chains: 1

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Immunoglobulin heavy constant gamma 4	A [auth H], B [auth A]	207	Homo sapiens	Mutation(s): 10  Gene Names: IGHG4
UniProt & NIH Common Fund Data Resources
Find proteins for P01861 (Homo sapiens) Explore P01861  Go to UniProtKB:  P01861
PHAROS:  P01861 GTEx:  ENSG00000211892

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.30 Å
• R-Value Free:  0.243 (Depositor), 0.242 (DCC) 
• R-Value Work:  0.201 (Depositor), 0.208 (DCC) 
• R-Value Observed: 0.203 (Depositor) 

Space Group: C 2 2 2₁

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 102.974	α = 90
b = 110.925	β = 90
c = 87.175	γ = 90

Software Package:

Software Name	Purpose
REFMAC	refinement
PDB_EXTRACT	data extraction
XDS	data reduction
XDS	data scaling
MOLREP	phasing

Structure Validation

Entry History 

Deposition Data

• Released Date: 2021-09-15 
Deposition Author(s): Oganesyan, V.Y., Shan, L., van Dyk, N., Dall'Acqua, W.F.

Revision History  

• Version 1.0: 2021-09-15
  Type: Initial release
  
• Version 1.1: 2021-09-22
  Changes: Database references
• Version 1.2: 2023-10-18
  Changes: Data collection, Refinement description
• Version 1.3: 2024-11-13
  Changes: Structure summary